Exploring determinants of psoriasis patients' treatment choices: a discrete-choice experiment study in the United States and Germany
Standard
Exploring determinants of psoriasis patients' treatment choices: a discrete-choice experiment study in the United States and Germany. / Feldman, Steven R; Poulos, Christine; Gilloteau, Isabelle; Mange, Brennan; Boehm, Katharina; Boeri, Marco; Naatz, Mandy; Augustin, Matthias.
in: J DERMATOL TREAT, Jahrgang 33, Nr. 3, 05.2022, S. 1511-1520.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Exploring determinants of psoriasis patients' treatment choices: a discrete-choice experiment study in the United States and Germany
AU - Feldman, Steven R
AU - Poulos, Christine
AU - Gilloteau, Isabelle
AU - Mange, Brennan
AU - Boehm, Katharina
AU - Boeri, Marco
AU - Naatz, Mandy
AU - Augustin, Matthias
PY - 2022/5
Y1 - 2022/5
N2 - BACKGROUND: Biologic psoriasis treatments are differentiated by efficacy, side effects, and other attributes.OBJECTIVE: Determine attributes of biologic psoriasis treatments that drive patients' treatment choices.METHODS: Respondents (USA: n = 300; Germany: n = 300) with moderate-to-severe psoriasis completed a discrete-choice-experiment survey, choosing between hypothetical treatments characterized by attributes with varying levels: chance of clear skin after 1 year, number of first-year treatments, first-year risks of mild-to-moderate injection site reaction (ISR) and serious infection, and years of proven efficacy/safety.RESULTS: U.S. respondents most valued clear skin (conditional relative importance, 1.88; p < .05). While other attributes were of generally equivalent importance, ISR risk outweighed serious-infection risk (1.06 vs. 0.70; p < .05). German respondents placed greatest importance on ISR risk (1.61; p < .05) and clear skin (1.49; p < .05).LIMITATIONS: Respondents evaluated hypothetical treatments and were recruited from web panels.CONCLUSIONS: Clear skin and ISR risk are stronger drivers of treatment choice than injection frequency and infection risk.
AB - BACKGROUND: Biologic psoriasis treatments are differentiated by efficacy, side effects, and other attributes.OBJECTIVE: Determine attributes of biologic psoriasis treatments that drive patients' treatment choices.METHODS: Respondents (USA: n = 300; Germany: n = 300) with moderate-to-severe psoriasis completed a discrete-choice-experiment survey, choosing between hypothetical treatments characterized by attributes with varying levels: chance of clear skin after 1 year, number of first-year treatments, first-year risks of mild-to-moderate injection site reaction (ISR) and serious infection, and years of proven efficacy/safety.RESULTS: U.S. respondents most valued clear skin (conditional relative importance, 1.88; p < .05). While other attributes were of generally equivalent importance, ISR risk outweighed serious-infection risk (1.06 vs. 0.70; p < .05). German respondents placed greatest importance on ISR risk (1.61; p < .05) and clear skin (1.49; p < .05).LIMITATIONS: Respondents evaluated hypothetical treatments and were recruited from web panels.CONCLUSIONS: Clear skin and ISR risk are stronger drivers of treatment choice than injection frequency and infection risk.
KW - Biological Products/therapeutic use
KW - Germany
KW - Humans
KW - Patient Preference
KW - Psoriasis/drug therapy
KW - Surveys and Questionnaires
KW - United States
U2 - 10.1080/09546634.2020.1839007
DO - 10.1080/09546634.2020.1839007
M3 - SCORING: Journal article
C2 - 33535847
VL - 33
SP - 1511
EP - 1520
JO - J DERMATOL TREAT
JF - J DERMATOL TREAT
SN - 0954-6634
IS - 3
ER -
